현대ADM
Financials
Valuation Metrics
현대ADM's Market Cap is ₩3819B. At end of 2025 it was ₩1478B. Ranked #529 of 2,405 in KR market (top 22%), #204 of 1,627 on KOSDAQ (top 13%), #55 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 24%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 381.88B KRW | KR#529/2,405 Sec#55/231 |
| Revenue | 8.34B KRW | KR#2,290/2,405 Sec#182/231 |
| Net Income | -16.36B KRW | KR—/2,405 Sec—/231 |
| Total Assets | 34.14B KRW | KR#2,300/2,405 Sec#214/231 |
| Net Assets | 22.94B KRW | KR#2,246/2,405 Sec#210/231 |
| Employees | 159 | KR#1,270/2,405 Sec#104/231 |
| Value | ||
| P/B | 16.65x | KR#2,385/2,405 Sec#222/231 |
| P/S | 45.77x | KR#2,357/2,405 Sec#198/231 |
| FCF Yield | -1.37% | KR—/2,405 Sec—/231 |
| Profitability | ||
| ROE | -71.34% | KR#2,308/2,405 Sec#211/231 |
| ROA | -47.94% | KR#2,345/2,405 Sec#215/231 |
| Op. Margin | -80.30% | KR#2,272/2,405 Sec#169/231 |
| Revenue Growth | -6.48% | KR#1,821/2,405 Sec#173/231 |
| Earnings Growth | -274.47% | KR#1,260/2,405 Sec#88/231 |
| Financial Health | ||
| Debt Ratio | 48.83% | KR#939/2,405 Sec#108/231 |
| Total Debt | 5.00B KRW | KR#1,775/2,405 Sec#170/231 |
| FCF | -5.22B KRW | KR#1,499/2,405 Sec#118/231 |
| Cash | 424.3M KRW | KR#2,356/2,405 Sec#225/231 |
| Current Ratio | 0.49x | KR#2,138/2,405 Sec#208/231 |
| Performance | ||
| 1Y Return | 116.46% | KR#60/2,405 Sec#3/231 |
| 1M Return | -14.96% | KR#1,578/2,405 Sec#160/231 |
| From 52W High | -71.41% | KR#2,097/2,405 Sec#175/231 |
| 1Y MDD | -81.53% | KR#2,303/2,405 Sec#210/231 |
| Trading | ||
| Volume | 343,432 shares | KR#227/2,405 Sec#13/231 |
| Trading Value | 2.06B KRW | KR#429/2,405 Sec#38/231 |
| Foreign Own. | 1.17% | KR#1,947/2,405 Sec#192/231 |
| Per Share | ||
| EPS | -256 KRW | KR—/2,405 Sec—/231 |
| BPS | 359 KRW | KR#2,385/2,405 Sec#228/231 |
Company Info
Established in 2003, this Contract Research Organization (CRO) was acquired by Hyundai Bioscience in 2024. It holds exclusive rights to drug delivery technology and provides comprehensive services to pharmaceutical companies and bio-ventures, including clinical trial design, monitoring, and data management. The company is developing breast and lung cancer treatments using inorganic material-based drug delivery system technology. It aims to become a global specialized oncology company through digital clinical trials leveraging AI, Big Data, and remote monitoring. Hyundai ADM is headquartered in Jongno-gu, Seoul.